Prosecution Insights
Last updated: November 18, 2026
Application No. 18/858,201

RNA VECTORS WITH HAIRPIN-LIKE INSERTS

Non-Final OA §103§112§DOUBLEPATENT
Filed
Oct 18, 2024
Priority
May 04, 2022 — provisional 63/338,290 +3 more
Examiner
VIJAYARAGHAVAN, JAGAMYA NMN
Art Unit
1633
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Silvec Biologics Inc.
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
26 granted / 42 resolved
+1.9% vs TC avg
Strong +51% interview lift
Without
With
+51.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
47 currently pending
Career history
97
Total Applications
across all art units

Office Action

§103 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Information Disclosure Statement The information disclosure statements (IDS) submitted on 08/27/2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. Election/Restrictions Applicant’s election without traverse of Group 2 drawn a vector comprising an exogenous RNA segment, wherein the exogenous RNA segment has certain free energy parameters in the reply filed on 09/22/2026 is acknowledged. Claims 21, 28-29, and 50-66 are pending and under examination. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 21, 28-29, and 50-66 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as failing to set forth the subject matter which the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the applicant regards as the invention. Claim 21 has phrases in parenthesis. The metes and bounds of this phrase are indefinite since it is unclear how these phrases or limitations relate to the scope of the claimed invention. It is also pointed out that the term “nt” be spelled out at the first instance of its usage. Claim 21 requires a minimum free energy in a range of -5 to +15 of -0.44 multiplied by the length of the insert -1.89. The value, however, lacks a unit for the minimum free energy. Appropriate clarification is required. Similar rejections apply for claims 55-56, 58-60, 63 and 65. Claim 21 recites “an apical loop at the end of one of the based paired regions wherein the exogenous segment has a minimum free energy in a range of -5 to +15 of -0.44 multiplied by the length of the insert (# of nt) - 1.89.” The wording of the claim is unclear especially in regard to relationship between -5 to +15 and -0.44 multiplied by the length of the insert (# of nt) - 1.89. For the sake of compact prosecution, the claim is interpreted to mean that the exogenous segment has a minimum free energy within a range of -5 kcal/mol to +15 kcal/mol of the free energy obtained by the value of -0.44 multiplied by the length of the insert (# of nt) - 1.89. Claim 28 requires an exogenous segment between 40 and 300. For the sake of compact prosecution, the claim is interpreted to mean 40-300 base pairs. However, this clarification is required in the claims. Claim 29 recites the limitation "the wildtype virus" in line 3. There is insufficient antecedent basis for this limitation in the claim. Claim 58 requires an exogenous segment that has a standard deviation of PE less than 0.5. Abbreviation PE needs to be spelled out at the first instance of their usage in the claims for greater clarity. Appropriate correction is required. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 21, 29, and 51 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The claim describes the relationship of the size of insert to the free energy of the RNA hairpin insert, using inserts CY1132-1329; CY1493-1525; CY2136-2218 and CY2220-2280 which have 61, 83 and 198 nucleotides using a line of best fit through the hairpin structures. The specification pointed out that “[w]hen comparing the DG of a synthetic construct to the DG of a natural hairpin-like structure of similar length, this formula (or a different formula derived from another wild type vector) may be used when a specific natural structure of similar length does not exist.” Thus, the specification clearly restricted the equation to predict the free energy of inserts with the size of the four tested hairpins. It is noted that the instant claim does not provide any restrictions to the size of the insert. Thus, Applicants were not in possession of the full scope of the claimed invention at the time of filing of the instant invention. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude”granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619(CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto- processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 21, 28-29, and 50-66 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 5-16 of copending Application No. 19/552,563. Although the claims at issue are not identical, they are not patentably distinct for the following reasons. Claim 5 of the ‘563 application is directed to an RNA vector that comprises an insert comprising a minimum free energy (ΔG) in kcal/mol (-0.27x plus 10) to (-0.49x minus 10), where x is the number of bases in the synthetic RNA segment. The claimed RNA vector falls within the parameters of the RNA vector are encompassed by ‘495 application. Claims 21, 28-29, and 50-66 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 39, 42, 43, 51-53, 55-57, and 59-62 of copending Application No. 18/311,495 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because both claim sets are drawn to related inventions for the reasons stated below. Claim 39 of the ‘495 application is directed to an RNA vector that comprises an insert comprising hairpin-like structure consists of a plurality of fully base- paired stacks, one or more internal non-base paired loops where each of which is located between two of the stacks, and an apical loop; and the nucleotides of said hairpin-like structure exhibit an Average Positional Entropy (APE) in the range of 0.01 to 0.75, and said hairpin-like structure exhibits a minimum free energy (ΔG) in kcal/mol that is within -10 to +15 of -0.43 multiplied by the length +1.17. The claimed RNA vector falls within the parameters of the RNA vector are encompassed by ‘495 application. Claims 55-66 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 23-26 and 28-37 of copending Application No. 18/311,552 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because both claim sets are drawn to related inventions for the reasons stated below. Claim 23 of the reference application encompasses the claimed RNA vector with the positional entropy required by claim 55. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 21, 28-29, and 50-53 are rejected under 35 U.S.C. 103 as being unpatentable over Simon et al. (WO 20/102210, published on 05/22/2020; See IDS 04/15/2023), in view of both Westerhout et al. (Nucleic Acids Res. 2007; hereinafter “Westerhout;” See IDS 08/27/2026) and Tortta et al (PLoS One. 2014 Nov 18; hereinafter “Tortta;” See PTO-892). Regarding claim 21: Simon was directed to a single stranded RNA vector suitable for introducing a therapeutic agent, such as 0a peptide, a protein or a small RNA, into a host plant. (See Simon Abstract). Simon also taught an “iRNA-based vector built on or derived from a plus-sense single-stranded RNA molecule using genetic components from an iRNA molecule, e.g., CYVaV” (See Simon [0076]). Figure 21 of Simon illustrated a stable hairpin insert at position 2301. Panel B shows the architecture of inserts comprising multiple hairpins, reading on the claimed a) two or more base-paired regions, b) one or more non- base-paired regions separating the base-paired regions and c) an apical loop at the end of one of the based paired regions. Simons did not teach that the exogenous segment has a minimum free energy in a range of -5 to +15 of -0.44 multiplied by the length of the insert (# of nt) - 1.89. Westerhout taught that “RNAi efficiency is influenced by local RNA structure of the target sequence.” (See Westerhout Abstract). Westerhout demonstrated that “increased RNAi efficiency on destabilized target hairpins is due to more efficient binding of the siRNA” (See Westerhout p.4325 col.2, para 3). Westerhout observed an inverse correlation between the overall target hairpin stability and RNAi efficiency within a specific thermodynamic stability ("G) range. Westerhout demonstrated that a ΔG window for shRNA-Pol destabilization without activating RNAi self-targeting, which may provide a guideline for other shRNAs. While Westerhout did not specifically teach the relationship of ΔG to the length of the insert, Trotta taught that RNA minimum free energy depends on sequence length. (See Trotta Abstract). Trotta used mathematical relationship between RNA length and free energy. Trotta expressly taught that “the additive and independent nature of the local free energy contributions suggests a linear relationship between computed MFE and sequence length.” (See Trotta p.2, col. 1, para 2). Accordingly, a person of ordinary skill in the art would have recognized that the folding free energy of an RNA hairpin insert varies with its nucleotide length and would have had reason to account for insert length when optimizing the thermodynamic stability of the hairpin inserts disclosed in Simon particularly in view of Westerhout’s teaching that RNA hairpin stability affects RNAi activity and vector performance. Regarding claims 28, 50 and 52: As indicated above, a person of ordinary skill would have recognized that RNA insert length as a parameter that affects the thermodynamic properties of the inserted RNA structure and would have has a reason to select appropriate length of insert through routine experimentation to obtain desired folding free energy, as further motivated by Westerhout’s teachings that RNA hairpin stability affects RNAi efficiency and vector performance. Regarding claim 29 and 51: Simon in Figures 21 did not use the hairpin structures in a lock and dock segment. Regarding claim 53: Simon taught that the thermodynamic stability of local RNA secondary structures affects viral vector viability. Simon demonstrated Fig. 25A where a parental stabilized construct containing 6 nt changes converting G:U pairs to G:C pairs in CYVaV-wt 3’stb was highly detrimental to viability. Simon demonstrated that destabilizing RNA segment restores viability. (See Simons [0062]) Accordingly, Simons established that the degree of G:C mediated stabilization of RNA secondary structures is a result-effective variable affecting viral vector performance. Selection of appropriate maximum number of G:C base pairs in the exogenous hairpin inserts to avoid excessive structure stabilization and maintaining desirable vector properties would have been obvious to a person of ordinary skill in the art in view of the teachings of Simon. Claim 54 is rejected under 35 U.S.C. 103 as being unpatentable over Simon et al. (WO 20/102210, published on 05/22/2020; See IDS 04/15/2023), in view of both Westerhout et al. (Nucleic Acids Res. 2007; hereinafter “Westerhout;” See IDS 08/27/2026) and Tortta et al (PLoS One. 2014 Nov 18; hereinafter “Tortta;” See PTO-892) and further in view of Schroeder et al (Biochemistry. 2000 Aug 8; hereinafter “Schroeder;” See PTO-892). Regarding claim 54: The teachings of Simons in view of Westerhout and Trotta are set forth above. It is noted that the cited references are silent with respect to the number of bases in the non-base paired regions. Schroeder taught that “broad range of thermodynamic stabilities, which depend on loop size, asymmetry, sequence, closing base pairs, and length of helix stems.” (See Schroeder Abstract). Therefore, the prior art established that the number of unpaired nucleotides in an internal loop is a result-effective variable affecting RNA secondary structure stability. Accordingly, a person of ordinary skill would have considered the number of bases in the non-base paired region as an optimizable variable, in view of Westerhout’s teachings regarding the folding stability and RNAi activity. Such consideration would have been consistent with the recognized importance of RNA conformational properties in determining RNA biological activity. Claims 55-60 and 62-66 are rejected under 35 U.S.C. 103 as being unpatentable over Simon et al. (WO 20/102210, published on 05/22/2020; See IDS 04/15/2023), in view of both Westerhout et al. (Nucleic Acids Res. 2007; hereinafter “Westerhout;” See IDS 08/27/2026) and Tortta et al (PLoS One. 2014 Nov 18; hereinafter “Tortta;” See PTO-892) and further in view of Garcia-Martin et al (PLoS ONE , 2015; hereinafter “Garcia-Martin;” See IDS 08/27/2026). Regarding claim 55-60: The teachings of Simons in view of Westerhout and Trotta are set forth above. It is noted that the cited references are silent with respect to the APE of the insert. Garcia-Martin taught an “algorithm to compute the derivational entropy for RNA secondary structures had previously been introduced, using stochastic context free gram mars (SCFGs).” (See Garcia-Martin Abstract). Garia-Martin further pointed out that “we plot the structural entropy as a function of temperature for known thermoswitches, such as the repression of heat shock gene expression (ROSE) element, we determine that the correlation between hammerhead ribozyme cleavage activity and total free energy is improved by including an additional free energy term arising from conformational entropy” (See Garcia-Martin Abstract). Accordingly, a person of ordinary skill would have had to consider structural entropy in addition to folding free energy when seeking to optimize RNA hairpin inserts disclosed in Simon, in view of Westerhout’s teachings regarding the folding stability and RNAi activity. Such consideration would have been consistent with the recognized importance of RNA conformational properties in determining RNA biological activity. It is also noted that the person would have had a reason to optimize various sub structures such as those detailed in claims 56-60 to optimize the entropy to achieve the desirable vector activity. Regarding claim 62: Simons is directed to a plant virus. Regarding claim 63-65: As indicated above, a person would have had a reason to optimize various sub structures such as those detailed in claims 56-60 to optimize the entropy to achieve the desirable vector activity. Regarding claim 66: Simons taught at [130] that “iRNA vector is provided that includes a non coding RNA insert that targets a plant response to a pathogen.” Although Simons does not expressly disclose that a second side of the exogenous segment has less than 90% complementarity to the first side, Simon teaches RNA inserts capable of forming secondary structures containing base-paired and non-base-paired regions. It would have been obvious to a person of ordinary skill in the art to adjust the degree of complementarity between opposing sides of an RNA hairpin insert to obtain a desired secondary structure and thermodynamic stability, including the incorporation of mismatches and unpaired regions, in view of the recognized relationship between RNA base pairing and folding stability. Accordingly, the degree of complementarity between the opposing sides of the exogenous RNA segment would have been a structural parameter available for optimization when designing the RNA insert. Claim 61 is rejected under 35 U.S.C. 103 as being unpatentable over Simon et al. (WO 20/102210, published on 05/22/2020; See IDS 04/15/2023), in view of both Westerhout et al. (Nucleic Acids Res. 2007; hereinafter “Westerhout;” See IDS 08/27/2026); Garcia-Martin et al (PLoS ONE , 2015; hereinafter “Garcia-Martin;” See IDS 08/27/2026) and Tortta et al (PLoS One. 2014 Nov 18; hereinafter “Tortta;” See PTO-892) and further in view of Serra et al (Nucleic Acids Res. 1993 Aug 11; hereinafter “Serra;” See PTO-892). Regarding claim 61: The teachings of Simons in view of Westerhout, Garcia-Martin and Trotta are set forth above. It is noted that the cited references are silent with respect to AU base pairings in exogenous segment. Serra taught that RNA hairpin stability depends on the identity of the loop closing base pairs and that A:U closing pairs introduce and additional free-energy penalty relative to more stabilizing closing pairs. In view of these teachings, one of ordinary skill in the art would have had a reason to adjust A:U base pair placement in the exogenous RNA hairpin inserts disclosed by Simon to obtain a folding free energy that maintains the desired secondary structure without restricting RNAi. Accordingly, the number of consecutive A:U base pairs would have been relevant consideration in selecting candidate RNA hairpin inserts. Conclusion No claim is free of art. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAGAMYA VIJAYARAGHAVAN whose telephone number is (703)756-5934. The examiner can normally be reached 9:00a-5:00p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christopher M. Babic can be reached at 571-272-8507. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAGAMYA NMN VIJAYARAGHAVAN/Examiner, Art Unit 1633 /EVELYN Y PYLA/Primary Examiner, Art Unit 1633
Read full office action

Prosecution Timeline

Oct 18, 2024
Application Filed
Oct 28, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760288
METHOD FOR TARGETED MODIFICATION OF SEQUENCE OF PLANT GENOME
4y 5m to grant Granted Oct 13, 2026
Patent 12709733
CELL CULTURE MEDIA
4y 3m to grant Granted Aug 18, 2026
Patent 12681006
METHODS OF GENERATING HUMAN ENDOMETRIAL STROMAL FIBROBLASTS AND THREE-DIMENSIONAL MULTI-LAYERED HUMAN ENDOMETRIAL TISSUE COMPOSITIONS
4y 2m to grant Granted Jul 14, 2026
Patent 12667621
RNA FORMULATIONS SUITABLE FOR THERAPY
4y 6m to grant Granted Jun 30, 2026
Patent 12637700
NOVEL METABOLIC PATHWAY FOR PRODUCING ITACONIC ACID AND METHOD FOR PRODUCING ITACONIC ACID USING SAME
2y 5m to grant Granted May 26, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
99%
With Interview (+51.4%)
Low
PTA Risk
Based on 42 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month